XML 70 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration and License Agreements - Bristol-Myers Squibb Company - Additional Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Apr. 25, 2017
USD ($)
Target
Jul. 07, 2014
USD ($)
Term
Target
Mar. 31, 2020
USD ($)
Jan. 31, 2018
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
Nov. 30, 2017
USD ($)
Mar. 17, 2017
Target
Dec. 31, 2016
USD ($)
Jan. 31, 2016
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Revenue recognized         $ 11,147 $ 12,853 $ 9,040 $ 21,893 $ 33,040 $ 53,163 $ 37,312              
Type of Revenue [Extensible List]                   us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember              
Deferred revenue                   $ 301,326 $ 284,760   $ 318,707          
Bristol Myers Squibb                                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Deferred revenue                   $ 169,200                
Collaborative Arrangement | Bristol Myers Squibb                                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Collaboration target research term   2 years                                
Number of additional collaboration target | Target   2                                
Research terms                   Each collaboration target had a two-year research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times.                
Extension of research term for each collaboration target   1 year                                
Upfront payment received $ 200,000 $ 50,000               $ 297,000                
Contingent milestone payments receivable                       $ 2,100,000   $ 10,000     $ 15,000 $ 10,000
Number of research targets selected | Target 8                                  
Total transaction price   304,700                                
Upfront fee received   250,000                                
Research and development service fees   17,700                                
Milestone payment received     $ 10,000 $ 12,000                            
Milestone payments received                   297,000                
Deferred revenue                   $ 169,200 $ 178,300              
Collaborative Arrangement | Bristol Myers Squibb | Pre Clinical Candidate                                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Contingent milestone payments receivable                                 $ 2,000  
Collaborative Arrangement | Bristol Myers Squibb | Third And Fourth Target                                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Target selection fee   $ 25,000                                
Collaborative Arrangement | Bristol Myers Squibb | New Drug Application for CTLA-4                                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Contingent milestone payments receivable                             $ 10,000      
Collaborative Arrangement | Maximum | Bristol Myers Squibb                                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Number of oncology target | Target   4                                
Number of collaboration target | Target   2                                
Period of nomination of additional target from effective date   5 years                                
Times of increments for extended collaboration target research time | Term   3                                
Collaborative Arrangement | Maximum | Bristol Myers Squibb | Each Of Two Additional Targets                                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Contingent milestone payments receivable   $ 25,000                                
Collaboration and License Agreement | Maximum | Bristol Myers Squibb                                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                    
Number of additional collaboration target | Target                               8